AcuCort AB (publ) (XSAT:ACUC)

Market Cap	116.75M -13.8%
Revenue (ttm)	1.68M +101.1%
Net Income	-27.13M
EPS	-0.11
Shares Out	234.44M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	36,997
Open	0.4970
Previous Close	0.4970
Day's Range	0.4800 - 0.5020
52-Week Range	0.4010 - 0.9500
Beta	1.41
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 5, 2026

About AcuCort AB

AcuCort AB (publ), a pharmaceutical company, identifies, develops, and commercializes drugs in Sweden. The company offers Zeqmelit, a dissolving, thin, and small oral film containing the glucocorticoid dexamethasone for the treatment of severe and acute allergic reactions, asthma, croup in children, nausea and vomiting associated with chemotherapy, and patients with COVID-19 with breathing difficulties and require oxygen therapy. AcuCort AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 5
• Stock Exchange: Spotlight Stock Market
• Ticker Symbol: ACUC

Financial Performance

In 2025, AcuCort AB's revenue was 687,000, an increase of 1.78% compared to the previous year's 675,000. Losses were -26.19 million, 50.5% more than in 2024.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 6, 2026

Data Sources Report a data error